Biotherapeutics Market

Biotherapeutics Market Overview

The global biotherapeutics market, valued at USD 481 billion in 2025, is projected to reach USD 528 billion in 2026 and USD 1,048 billion by 2035, with a 7.9% CAGR during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Biotherapeutics Industry: In Summary

• Biotherapeutics industry is anticipated to witness upward trajectory owing to the growing shift towards biologics for treating wide range of diseases, including cancer, infectious diseases, and autoimmune disorders.
• The recent USFDA accelerated approval of AbbVie's Emrelis™ (telisotuzumab vedotin-tllv) for adult patients with previously treated advanced non-small cell lung cancer is poised to significantly capture the attention of industrial players. This approval is particularly impactful as it validates novel therapeutic approaches and underscores the market potential for targeted oncology treatments, thereby encouraging further investment and development in the field.
• North America currently holds maximum share (35%) of the market due to the high demand for advanced therapies, favorable regulatory framework, and accelerated research on biotherapeutics.
• Companies, such as Atkis Oncology (US) and Alpha-9 Oncology (Canada) are rising investments in funding rounds, which is expected to continue to shape the industrial landscape.
• AstraZeneca’s (UK) recent acquisition of EsoBiotec (UK) for an upfront payment of USD 425 million significantly expands its in vivo cell therapy portfolio. This strategic move highlights a growing trend of acquisitions aimed at solidifying market positions and accelerating innovation within the biopharmaceutical sector.
• Monoclonal antibody segment is currently dominating the market, and the trend is likely to remain unchanged. This is potentially due to the growing demand for monoclonal antibodies to treat a broad range of disease indications.

Biotherapeutics Market Overview

Biotherapeutics industry is gaining rapid momentum driven by the growing shift towards biologics for treating wide range of diseases. It refers to the biologics therapies that are derived from living cells, such as antibodies, proteins, and nucleic acids. These biologics have potential to treat patients with cancer, infectious diseases, and autoimmune disorders. The market landscape for biotherapeutics has evolved significantly due to the growing preferences for antibody-based biotherapeutics to target cancerous cells and expanding usage across other therapeutic areas.

To date, several biotherapeutics has been approved by the USFDA, including cell therapies (such as stem cell therapy), monoclonal antibodies, cytokines based therapies, B-cell inhibitors and vaccines. Furthermore, in May 2025, the USFDA has approved Emrelis™ (telisotuzumab vedotin-tllv) developed by AbbVie (US) to treat adult patients with metastatic and non-squamous non-small cell lung cancer.

Furthermore, several drugs are currently being investigated under clinical trials at different stages. These accelerated approval from the USFDA and rising clinical pipelines caught the attention of industrial players to initiate drug discovery and development.

Additionally, companies, such as Atkis Oncology (New York) and Alpha-9 Oncology (Canada) raised significant investments which are expected to continue to shape the industrial landscape. Owing to these ongoing initiatives and investment, we believe biotherapeutics market will continue to grow at a steady rate during the forecast period.

Biotherapeutics Market: Report Attributes

One of the key objectives of the biotherapeutics market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global biotherapeutics market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of product, route of administration, application area, end user, geographical regions, and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

What are the Recent Developments in Biotherapeutics Market?

Several recent developments have taken place in the field of biotherapeutics, and we outlined some of these below.

• In April 2025, Johnson & Johnson (US) announced the USFDA approval of IMAAVY™ (nipocalimab-aahu) to treat generalized myasthenia gravis in adults and children 12 years and older.
• In February 2025, Medigene (Germany) and EpimAB Biotherapeutics (China) entered into a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell engagers to treat immune-related disorders.
• In February 2025, Biogen (US) and Stoke Therapeutics (US) announced the strategic collaboration to develop and commercialized zorevunersen (first-in-class) disease modifying biotherapeutic to treat Dravet syndrome, in all territories outside the US, Canada and Mexico.

Biotherapeutics Market Segmentation Insights

The market report provides comprehensive information on biotherapeutics industrial players who are currently active across various segments of the industry as mentioned in the table below.

Biotherapeutics Market: Market Segmentation

Industry Experts on Biotherapeutics Market

Biotherapeutics industry is setting a new benchmark and continue to gain momentum with the growing focus on next generation biotherapeutics.

“The first thing that comes to mind is lots of opportunities, because this is really going back to the base of innovation,” said Benoit Gourdier, executive vice-president and head, Bioscience Production Segment, Avantor.

Where once the biopharma industry was dominated by monoclonal antibodies (mAbs), the industry can now expect to see a wave of newer, more innovative therapies aimed at achieving precision treatment. “Starting 25-30 years ago, it was really mAbs, mAbs, mAbs, and traditional vaccines,” Gourdier said, adding, “We grew up in this environment. Now we have this diverse portfolio of modalities, so [that will provide] lots of opportunities to go after, to learn.”

Biotherapeutics Market Share Insights

Market Share by Type of Product: Monoclonal Antibodies Holds the Highest Share

• Based on the type of product, the global market is segmented into monoclonal antibodies, cell therapies, clotting factors, cytokines, enzymes, hormones, and vaccines. According to the biotherapeutics market report, monoclonal antibodies are currently dominating the market by holding 35% of overall revenue share, and the trend is likely to remain unchanged. This dominance is due to the growing approval of monoclonal antibodies based therapies to treat cancer and other disease indications.
• It is worth mentioning that cell therapies segment is likely to show robust growth at a higher CAGR during the forecast period. Cell therapies are gaining traction to treat wide range of diseases due to higher efficacy and target specificity.

Market Share by Route of Administration: IV Injections Segment Holds the Largest Share

• This segment highlights the distribution of global market across different route of administration, such as IV injection or infusion, subcutaneous and transdermal. Currently, IV injections or infusion segment holds the highest share of the biotherapeutics market forecast. This is likely to be the fact that IV injection is a fundamental route of administration specifically for large molecules.
• Notably, in the long run, the subcutaneous segment is likely to grow at a higher CAGR during the forecast period. Subcutaneous injections are slightly less invasive and ideal for delivering complex biologics. Hence, healthcare professionals are encouraging the use of subcutaneous injections to manage chronic conditions.

Market Share by Application Area: Cancer Segment is Dominating the Market

• Based on application area, the global market is segmented into cancer, diabetes, autoimmune diseases, infectious diseases, and neurological diseases. According to the biotherapeutics market analysis, cancer segment holds the highest share of the market. This can be attributed to the growing adoption of monoclonal antibodies and immune checkpoint inhibitors for the treatment of cancer.
• In the long run, neurological diseases segments is likely to show lucrative growth, anticipated to grow at a higher CAGR during the forecast period. This robust growth is primarily driven by the increasing global prevalence of neurodegenerative disorders like Alzheimer's and Parkinson's, a robust and expanding pipeline of novel biotherapeutics (including gene and cell therapies), and significant advancements in diagnostic technologies enabling earlier and more precise disease detection. Furthermore, the aging global population contributes substantially to the rising patient pool with neurological conditions, fueling demand for innovative treatments.

Market Share by End User: Hospitals Holds the Largest Share of the Market

• On the basis of end user, the global market is segmented into hospitals, research institutions, and specialty clinics. It is worth noting that the segment for hospitals occupies the highest market share for biotherapeutics. This can be attributed to healthcare professionals increasingly leveraging biotherapeutics for their targeted efficacy and expanding utility across a diverse range of complex disease indications..
• In addition, the availability of healthcare experts, and advanced drug delivery technologies in hospitals is likely to maintain dominance in the upcoming years. Driven by the preferences of high adoption of biotherapeutics in hospitals, this segment will continue to grow at a steady CAGR during the forecast period.

Market Share by Geographical Regions: North America Holds the Highest Share

• The global market is distributed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to biotherapeutics market forecast, presently North America holds the highest share (35%) of the market. This is likely to be the growing demand for advanced therapies, favorable regulatory framework, and accelerated research on biotherapeutics by industrial players established in the region.
• In Asia-Pacific, the market for biotherapeutics is expected to grow at a substantial CAGR during the forecast period. This is potentially due to the growing incidence of chronic conditions that necessitated the demand for advanced therapeutics in this region. Additionally, increasing research on the next generation biotherapeutics is likely to support the growth of market in Asian region.

Biotherapeutics Market: Report Deliverables

Biotherapeutics Market Major Takeaways

The “Biotherapeutics Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities future opportunities within the biotherapeutics industry, during the forecast period.

How is Biotherapeutics Market Competitive Landscape Fragmented?

The biotherapeutics market witness intense competition among established pharmaceutical companies and emerging biotechnology companies. Some of the established leaders include Abbott (US), AGC Biologics (US), Selexis (Geneva), Pfizer (US), Merck (US), and Roche (Switzerland). These companies are actively pursuing partnerships, acquisitions, and collaborations to enhance their product portfolios and expand their research on next generation biologics and drug delivery technologies.

For instance, in March 2025, Oxford BioTherapeutics (US), a clinical stage oncology company announced a multi-year collaboration with Roche (Switzerland) with an aim of discovering first-in-class antibody-based therapeutics to treat cancer. This collaboration leverages Oxford BioTherapeutics' proprietary OGAP®-Verify discovery platform to identify novel tumor targets, combining it with Roche's extensive drug development and commercialization expertise. Such alliances are crucial in accelerating the notoriously lengthy and costly drug discovery process, enabling companies to share risks, pool resources, and bring innovative therapies to patients.

What is the Current Biotherapeutics Market Size?

In 2025, the global market for biotherapeutics is USD 528 billion in 2026 and is projected to reach USD 1,048 billion by 2035. The major drivers of the market include rising adoption of biologics, monoclonal antibodies, cell and gene therapies, biosimilars, and other advanced biotherapeutic modalities. In terms of product, monoclonal antibodies are currently dominating the market. Monoclonal antibodies are widely gaining popularity as targeted therapy to treat diseases, including cancer and chronic conditions. Therefore, in order to enhance the production of mAB based therapeutics, several market players are undergoing monoclonal antibody manufacturing process optimization, which is further expected to drive the market in the future.

What are the Major Biotherapeutics Market Drivers?

Rising Incidence of Chronic Diseases

The unprecedented growth of biotherapeutics industry is likely to be driven by the rising prevalence of chronic diseases, such as bowel disease and cancer. Notably, cancer has been a major concern for the healthcare industry, resulting into millions of deaths every year. According to the National Health Institutes stats, nearly 618,120 deaths from cancer are projected to occur in the US. This high mortality rate has underscored the requirement for targeted therapies to treat cancer patients.

Increasing Focus on Microbiome Research

Furthermore, the increasing focus on microbiome research to understand the role of microbiomes in disease is likely to drive this market during the forecast period. In addition, live biotherapeutics are further gaining traction to treat metabolic disorders and neurological disorders.

What are the Challenges in Biotherapeutics Market?

Complex Regulatory Framework for Drug Approval

The market for biotherapeutics has shown robust growth due to the rising demand for therapeutic drugs for treating chronic conditions. However, there are several challenges that may hinder the biotherapeutics cell line development market growth. Some of the notable challenges include the USFDA guidelines for biotherapeutic product approval and manufacturing processes particularly for emerging therapeutic modalities like live biotherapeutics.

High Cost, Scaling Challenges and Requirement of Specialized Storage

Furthermore, the prolonged clinical validation requirements for biological products create substantial time and cost barriers. Moreover, the inherent complexity of biologics and requirement of specialized equipment for manufacturing may create challenges in scaling up biotherapeutic production. In addition, the requirement for specialized storage and supply chain infrastructure may limit the accessibility of these drugs.

What are the Top Biotherapeutics Market Trends?

Expanding Applications of Biotherapeutics in Different Therapeutic Areas

The biotherapeutics market presents substantial opportunities for expansion into new therapeutic areas, particularly in neurological disorders and metabolic diseases where traditional treatments have shown limited efficacy. The infectious diseases segment is experiencing rapid growth, fueled by recent pandemic preparedness initiatives and emergency use authorizations for novel antibody-based treatments.

Growing Recognition of Liver Biotherapeutics for Personalized Treatment

In addition, the emerging recognition of live biotherapeutics for highly personalized biotherapeutic interventions creates lucrative opportunities for market players. Furthermore, the industry is shifting toward patient-centric development approaches that prioritize real-world evidence generation and patient-reported outcomes. This patient-centric approach is further creating unique value propositions for biotherapeutic products that demonstrate tangible improvements in patient quality of life. In addition to patient-centric drug development, industrial players are emphasizing custom protein engineering solutions for biotherapeutics that aid in modifying proteins at a molecular level to achieve specific therapeutic goals.

How Do Partnerships and Collaborations Drive Growth of Biotherapeutics Industry?

It is important to highlight here that industrial players are focusing on acquisitions, collaborations, and partnerships to expand product portfolio and develop next-generation biotherapeutics. Notably, partnerships and collaborations are important for the growth of this industry. The complex regulatory framework, high-risk nature and costly drug discovery and development, make collaborations a vital step for industry progress.

In order to strengthen position, several industrial players are expanding acquisitions, collaborations, and partnerships. For instance, AstraZeneca (UK) announced to acquire EsoBiotech (Belgium) with an upfront payment of USD 425 million in USD 1 billion deal to expand in vivo cell therapy portfolio. With this acquisition, EsoBiotec (Belgium) will become a wholly owned subsidiary of AstraZeneca (UK) and is poised to strengthen AstraZeneca’s position in oncology and immune-mediated diseases by integrating a scalable cell therapy approach into its pipeline.

Biotherapeutics Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the biotherapeutics industry, across different geographies. Amongst other elements, the market report includes:

• An Infographic Executive Summary
• Market Landscape of Biotherapeutics
• Company Competitiveness Analysis
• Company Profiles
• SWOT Analysis
• Market Impact Analysis
• Market Forecast Analysis

From the Author’s Desk

Author’s View on Biotherapeutics Market

The biotherapeutics market is likely to sustain exponential growth over the next decade, driven by convergence of several transformative factors including advanced biotechnology platforms, improved regulatory frameworks, and increasing healthcare investment in biological solutions. The live biotherapeutics segment, in particular, represents a paradigm shift toward microbiome-based medicine that could fundamentally alter treatment approaches for chronic diseases.

Furthermore, cancer therapeutics and biotherapeutics market consolidation is likely to accelerate as larger pharmaceutical companies acquire specialized biotechnology firms to enhance their biological product portfolios. Strategic partnerships and collaborations will become increasingly important for accessing specialized manufacturing capabilities and novel therapeutic platforms.

Glossary

• Biotherapeutics: Treatments derived from living organisms or their products, including proteins, antibodies, nucleic acids, cells, and tissues used for disease treatment.
• Live Biotherapeutics (LBPs): It refers to the biotherapeutics that are designed by using living microorganisms to prevent, treat, or cure diseases.
• Monoclonal Antibodies: It refers to the recombinant protein of laboratory-produced proteins that mimic immune system responses to fight specific pathogens or disease targets.
• Microbiome: The collective genetic material of microorganisms living in the human body, particularly the digestive system.